Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 5/20 | 0.76 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.76 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.76 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.76 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | BRD4 | O60885 | 2/20 | 0.58 |
| ▸ | BRD2 | P25440 | 1/20 | 0.58 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.58 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4566277 | 0.91 | MEN1 (0.77) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL25286006 | 0.90 | ALDH1A1 (0.71) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL381684 | 0.89 | PDE4A (0.71) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL11400162 | 0.88 | MEN1 (0.69) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL10394932 | 0.88 | MEN1 (0.69) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL17682216 | 0.86 | SMN1; SMN2 (0.64) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL3902928 | 0.86 | PDE4A (1.00) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL7464482 | 0.85 | PDE4A (0.86) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL16675435 | 0.84 | MAPK1 (0.64) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL10955005 | 0.84 | MAPK1 (0.64) | PDE4AADORA2APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025046257-A1 | A SUBSTANTIALLY PURE PROPENTOFYLLINE AND PREPARATION THEREOF | HIKAL LIMITED (IN) | 2025-03-06 | — | — | WO | claimed |
| EP-0960884-B1 | Process for the production of 3,7-dialkylxanthins from 3-alkylxanthins | AVENTIS PHARMA GMBH (DE) | 2002-10-09 | — | — | EP | claimed |
| EP-0597377-B1 | Process for the production of 3,7-Dialkylxanthine from 3-Alkylxanthine | AVENTIS PHARMA GMBH (DE) | 2000-08-16 | — | — | EP | claimed |
| EP-0960884-A1 | Process for the production of 3,7-dialkylxanthins from 3-alkylxanthins | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-12-01 | — | — | EP | claimed |
| US-5550041-A | PRODUCING 3-METHYL-7-ALKYLXANTHINE BY CULTIVATING PSEUDOMONAS TRANSFORMED TO PRODUCE CAFFEINE DEMETHYLASE IN NUTRIENT MEDIUM CONTAINING 1,3-DIMETHYL-7-ALKYLXANTHINE | AMANO PHARMACEUTICAL CO., LTD. (JP) | 1996-08-27 | — | — | US | claimed |
| EP-0597377-A1 | Process for the production of 3,7-Dialkylxanthine from 3-Alkylxanthine | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-05-18 | — | — | EP | claimed |
| JP-5139976-A | — | — | None | — | — | JP | disclosed |
| JP-7316156-A | — | — | None | — | — | JP | disclosed |
| JP-6192047-A | — | — | None | — | — | JP | disclosed |
| WO-2025046257-A1 | A SUBSTANTIALLY PURE PROPENTOFYLLINE AND PREPARATION THEREOF | HIKAL LIMITED (IN) | 2025-03-06 | — | — | WO | disclosed |
| US-20250066413-A1 | COMPOSITIONS FOR TREATMENT OF INFLAMMATION | METRO INTERNATIONAL BIOTECH, LLC | 2025-02-27 | — | — | US | disclosed |
| EP-4452279-A1 | COMPOSITIONS FOR TREATMENT OF INFLAMMATION | Metro International Biotech, LLC (US) | 2024-10-30 | — | — | EP | disclosed |
| CN-118541157-A | Composition for treating inflammation | 麦德龙国际生物科技有限责任公司 | 2024-08-23 | — | — | CN | disclosed |
| EP-0268585-A1 | TERTIARY HYDROXYALKYLXANTHINES, THEIR MANUFACTURING PROCESS, MEDICINES CONTAINING THEM AND USE THEREOF. | HOECHST AG (DE) | 1988-06-01 | — | — | EP | disclosed |
| EP-0264081-A2 | Oxadiazolyl alkyl purin derivatives, their preparation and their use in pharmaceutical compositions | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) | 1988-04-20 | — | — | EP | disclosed |
| WO-1987000523-A2 | TERTIARY HYDROXYALKYLXANTHINES, THEIR MANUFACTURING PROCESS, MEDICINES CONTAINING THEM AND USE THEREOF | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-01-29 | — | — | WO | disclosed |
| US-4289776-A | VASODILATORS, FIBRINOLYTIC | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-09-15 | — | — | US | disclosed |
| EP-0023032-A1 | Process for the preparation of oxoalkylxanthines | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-01-28 | — | — | EP | disclosed |
| US-4207321-A | PROMOTES BLOOD PERFUSION | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-06-10 | — | — | US | disclosed |
| US-4108995-A | CEREBRAL BLOOD FLOW | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066413-A1 | COMPOSITIONS FOR TREATMENT OF INFLAMMATION | NQO1, NAMPT, MPO | PDE4A 371/4885ADORA2A 543/4885PDE4B 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.